About ten thousand years ago, a group of Neolithic farmers in the Balsas River Basin of Mexico began writing a genome. They did not know it. The crop they produced,…
Adrian Woolfson helped make genome writing a conversation serious people are having. He also helped make it one of the most charged arguments in modern biomedicine. Part II examines Eric…
Adrian Woolfson trained under a Nobel laureate at Cambridge, ran global oncology programs at the world’s largest pharmaceutical companies, and led research and development at Sangamo Therapeutics during the first…
Adrian Woolfson oversaw the first clinical trial to edit a living person’s DNA at Sangamo Therapeutics. At Genyro, the San Diego biotech he cofounded with Brian Hie and Kaihang Wang,…
For four decades, a single protein drove roughly a third of all human cancers, and nobody could build a drug against it. Here is why that story is finally changing,…
Five Nobel laureates are quietly orbiting Isomorphic Labs, the Alphabet-backed company trying to use artificial intelligence to end the world’s deadliest diseases. What they are building would have been science…
For decades, cardiac amyloidosis was a diagnosis cardiologists whispered and patients rarely heard. In 2026, tafamidis, acoramidis, RNA silencers, and a CRISPR gene editing therapy are transforming ATTR care and…
Phase 3 trials of pelacarsen, olpasiran, lepodisiran, and the first oral Lp(a) drug muvalaplin are ending cardiology’s sixty year blind spot on lipoprotein(a), a genetically determined particle that silently elevates…
For the first time in pharmaceutical history, molecules designed almost entirely by artificial intelligence are surviving Phase 2 trials in real patients. From Insilico’s rentosertib to Isomorphic Labs’ multi-billion dollar…
Roughly one in five adults worldwide carries a genetic condition that roughly doubles their lifetime cardiovascular risk. Lipoprotein(a) is invisible to standard cholesterol panels, cannot be lowered by diet or…
Zach RobertsSign up for personalized wellness coaching and the Daily Discovery Newsletter.